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Hyaluronan (HA), one of the major structural extracellular components in cartilage, regulates
cellular responses via receptors such as CD44. However, the direct effects of HA on osteoblastic dif-
ferentiation has not been studied in detail. Here, we investigated the effects of HA (molecular
weight: 900–1200kDa) on osteoblastic differentiation that was induced by bone morphogenetic pro-
tein (BMP) in C2C12 cells (mouse myoblastic cells) and ST2 cells (mouse bone marrow cells). BMP-
induced osteoblastic differentiation and Smad1/Smad5/Smad8 phosphorylation were downregu-
lated by HA. Use of the CD44-blocking antibody restored HA-induced inhibition of osteoblastic dif-
ferentiation and Smad1/Smad5/Smad8 phosphorylation. Our results indicate that HA inhibits BMP-
induced osteoblastic differentiation through the CD44 receptor.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hyaluronan (HA) is a linear polymer, which is characterized by
repeated disaccharide units of D-glucuronate and N-acetyl-D-gluco-
samine [1,2]. HA is a major component of the extracellular matrix
of cartilage, which regulates cell proliferation, differentiation,
motility, and adhesion directly via receptors such as CD44 [2,3].
In addition to being expressed by many cell types [4,5], CD44 is
one of the major HA receptors. HA participates in many functions
via the CD44 receptor such as regulation of cartilage metabolism,
including osteoclastogenesis [6–8]. However, the direct effects of
HA on osteoblastic differentiation have rarely been studied [9].
Bone morphogenetic protein-2 (BMP-2), a member of the trans-
forming growth factor-b superfamily, was originally identiﬁed as
an inducer of ectopic bone formation [10]. BMP-2 is known to play
important roles in bone formation, bone regeneration [11], fracture
healing [12], and osteophyte formation [13]. The binding of BMP-2
to type I and II serine/threonine kinase receptors induces Smad
phosphorylation. Phosphorylated Smads then translocate from
the cytoplasm to the nucleus to regulate the transcription of vari-
ous genes, such as alkaline phosphatase (ALP), runt-related tran-
scription factor 2 (Runx2), and osteocalcin [14]. BMP-2 alsoserves as a useful experimental model of osteoblastic differentia-
tion in vitro because undifferentiated mesenchymal cells, myo-
blasts, or osteoprogenitor cells can be differentiated into
osteoblasts by BMP-2 [15].
In this study, we investigated the effects of HA on bone forma-
tion using BMP-induced osteoblastic differentiation in mouse myo-
blast cells (C2C12 cells) and mouse bone marrow cells (ST2 cells).
These cells differentiate into osteoblasts after treatment with BMP-
2 as well as primary osteoblasts and they are known to be models
for the study of osteoblast differentiation [16,17]. We examined
whether the major receptor for HA, CD44, is involved in BMP-
induced osteoblastic differentiation. Furthermore, we investigated
the potential crosstalk between HA–CD44 and BMP–Smad
signaling.
2. Methods
2.1. Cell culture
The experimental design of the study is summarized in Fig. 1.
C2C12 and ST2 cells were obtained from Riken Cell Bank (Tsukuba,
Japan). C2C12 cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal
bovine serum (FBS; Hyclone, Road Logan, UT, USA). ST2 cells were
maintained in RPMI 1640 (Invitrogen) containing 10% FBS in a
humidiﬁed atmosphere of 5% CO2 at 37 C. C2C12 cells were trea-
ted with HA at different concentrations in the presence of 300 ng/
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transferred to growth medium supplemented with 0.1 mM ascor-
bic acid (Sigma–Aldrich, St. Louis, MO, USA) and 4 mM b-glycero-
phosphate (Sigma–Aldrich), and treated with HA at different
concentrations in the presence of 100 ng/ml rhBMP-2.
2.2. Immunocytochemistry
To examine CD44 expression, C2C12 and ST2 cells were plated
on chamber slides and ﬁxed with 4% paraformaldehyde for
30 min, blocked with 1% bovine serum albumin (BSA; Sigma–
Aldrich) for 1 h, incubated overnight with a primary antibody at
4 C, and then incubated for 1 h with a ﬂuorescein isothiocyanate
(FITC)-conjugated secondary antibody. The primary antibody was
anti-CD44 monoclonal antibody [Becton, Dickinson & Co (BD),
Franklin Lakes, NJ, USA]. The clone used for the anti-CD44 mono-
clonal antibody was IM7.
2.3. Flow cytometry (FACS)
Cells were scraped gently and washed with phosphate-buffered
saline (PBS). Approximately 5  105 cells were suspended in
Hank’s balanced salt solution containing 1% BSA on ice. Cells were
incubated on ice with APC anti-CD44 (BD Bioscience, Franklin
Lakes, NJ USA) for 30 min. Fluorescence was measured using the
BD FACSCanto™ II system.
2.4. Proliferation assay
Cells were cultured in 96-well plates at a density of 2  104/cm2
with or without rhBMP-2 at concentrations of 300 ng/ml or 100 ng/Fig. 1. Flow chart of the experimental design. For detailed description see the
Section 2. All of the quantitative experiments were performed at least in triplicate
and each experiment was performed a minimum of three times to consider the
effects of biological variation.ml and HA (Artz from Seikagaku, Kogyo Co., Tokyo, Japan) at con-
centrations of 0, 50, 500, or 1000 lg/ml. After 3 days, cell prolifer-
ation was assessed using the PremixWST-1 Cell Proliferation Assay
System (Takara Bio, Otsu, Japan), according to the manufacturer’s
instructions.
2.5. ALP staining
Cells were plated on 24-well plates at a density of 2  104 cells/
well. After 24 h, the culture medium was replaced with growth
medium containing rhBMP-2 and HA at concentrations of 0, 50,
500, or, 1000 lg/ml, followed by culture for 3 days. Cells were
washed with PBS and ﬁxed for 15 min with 10% formalin at room
temperature. After ﬁxation, cells were incubated for 1 h at room
temperature with the ProtoBlotR AP system and stabilized sub-
strate (Promega, Madison, WI, USA).
2.6. ALP activity
To measure ALP activity, cells were washed with PBS and lysed
in mammalian protein extraction reagent (M-PER; Pierce, Rock-
ford, IL, USA), according to the manufacturer’s instructions. ALP
activity was measured using the LabAssay™ ALP system (Wako
Pure Chemicals Industries Ltd., Osaka, Japan) with p-nitrophenyl
phosphate as the substrate. To normalize the enzyme activity,
the protein content was measured using a bicinchoninic acid pro-
tein assay kit (Pierce, Rockford, IL, USA).
2.7. Reverse transcription polymerase chain reaction and quantitative
real-time polymerase chain reaction
Total RNA was isolated using TRIzol (Invitrogen) according to
the manufacturer’s instructions. cDNA was synthesized using the
Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics,
Mannheim, Germany). RT-PCR was performed using PCR Master
Mix (Promega) and the following primers: ALP, forward 50-GCCCT
CTCCAAGACATATA-30 and reverse 50-CCATGATCACGTCGATATCC-
30; Runx2, forward 50-GCTTGATCACTCTAAACCTA-30 and reverse
50-AAAGCCGAGCTG CCAGAGCTT-30; osterix, forward 50-GAA-
GAAGCTCACTATGGCTC-30 and reverse 50-GAAAAGCCAGTTGCA-
GACGA-30; osteocalcin, forward 50-CAAGTCCCACACA GCAGCTT-30
and reverse 50-AAAGCCGAGCTGCCAGAGTT-30; CD44, forward 50-
GCACCCCAGAAGGCTACATTT-30 and reverse 50-TCTGCCCA-
CACCTTCTC CTACTAT-30 [18]; and GAPDH, forward 50-TGAACGG-
GAAGCTCACTGG-30 and reverse 50-TCCACCACCTGTTGCTGTA-
30.The PCR products were separated by agarose gel electrophoresis
and detected using ethidium bromide. We conducted real-time
PCR using a Light Cycler system (Roche Applied Science, Basel,
Switzerland). By using a Quantitect SYBR Green PCR Kit (Qiagen,
Venlo, Limburg, The Netherlands), each cDNA sample was evalu-
ated in triplicate reactions. Expression values were normalized to
GAPDH. The following primers were used: ALP, forward 50-
AATCGGAACAACCTGACTGACC-30 and reverse 50-TCCTTCCAGCA-
AGAAGAA-30; Runx2, forward 50-GCCCAGGCGTATTTCAGAT-30 and
reverse 50-TGCCTGGCTCTTCTTACTGAG-30; Osterix, forward 50-
AGGCACAAAGAAGCCATAC-30 and reverse 50-AATGAGTGAGG-
GAAGGGT-30; Osteocalcin, forward 50-CTCACTCTGCTGGCCCTG-30
and reverse 50-CCGTAGATGCGTTTGTAGGC-30; GAPDH, forward
50-TGTCCGTCGTGGATCTGAC-30 and reverse 50-CCTGCTTCAC-
CACCTTCTTG-30.
2.8. Western blotting
The Smad signals were analyzed by monitoring the phosphory-
lation levels of receptor-activated Smads (Smad1, Smad5, and
Smad8; Smad1/5/8). Cells were treated with 500 lg/ml HA in the
Fig. 2. CD44 expression in C2C12 and ST2 cells. (A) RT-PCR of the mRNA of the
CD44 gene. Lane 1: DNA ladder, lane 2: negative control, lane 3: C2C12 cells, lane 4:
ST2 cells. (B) Representative example of CD44 protein expression in C2C12 cells and
ST2 cells: (a) C2C12 cells; (b) ST2 cells. Counterstaining with DAPI (blue) and CD44
(green), scale bar = 20 lm. (C) CD44 expression in C2C12 and ST2 cells based on
ﬂow cytometry: (a) C2C12 cells; (b) ST2 cells. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
K. Kaneko et al. / FEBS Letters 589 (2015) 447–454 449presence or absence of rhBMP-2 for 30 min. Next, cells were lysed
rapidly on ice using Blue Loading Buffer Reagents (Cell Signaling
Technology, Beverly, MA, USA) containing 0.125 M dithiothreitol.
These samples were subjected to 4–12% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and then transferred to nitro-
cellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA).
After blocking with 0.1% Tween 20 and PBS containing 3% BSA,
the membranes were incubated with speciﬁc primary antibodies
against phospho-Smad1/5/8, Smad1, or b-actin rabbit monoclonal
antibodies (Cell Signaling Technology, Beverly, MA, USA). The
membranes were incubated with horseradish peroxidase-conju-
gated secondary antibodies (GE Healthcare) and enhanced chemi-
luminescence (ECL) reagents (GE Healthcare).
2.9. RhoA activity
RhoA activity was assayed using rhotekin beads. Cells were
treated with 500 lg/ml HA in the presence of rhBMP-2 for
30 min. RhoA activity assay was performed using the Rho Activa-
tion Assay Kit (Millipore, Billerica, MA, USA). Cells were lysed using
lysis buffer, and the cell lysates were clariﬁed by centrifugation,
before incubation with Rho Assay Reagent for 45 min to selectively
bind the activated RhoA in a pull-down assay. Whole-cell lysates
were immunoblotted directly to determine the total amount of
RhoA, where RhoA was detected by Western blotting.
2.10. Neutralization studies using anti-CD44 antibody
Cells were pretreated with CD44-blocking antibody for 2 h
before stimulation with different concentrations of HA in the pres-
ence of rhBMP-2. Anti-CD44-blocking rat antibody (Calbiochem,
San Diego, CA, USA) [19] was used in the neutralization assay for
ALP staining, ALP activity analysis, Western blotting, as well as to
determine RhoA activity. The clone used for anti-CD44 blocking
was A020. Rat IgG antibody was used as the negative control,
which was purchased from Santa Cruz Biotechnology (Dallas, TX,
USA).
2.11. Effects of synovial ﬂuid on osteoblastic differentiation
The effects of human synovial ﬂuids on osteoblastic differentia-
tion were studied by evaluating ALP activity. Synovial ﬂuid sam-
ples were obtained from patients in the Department of
Orthopedic Surgery at Osaka University. Written informed consent
was obtained from each patient and the study was approved by the
Ethical Committee of Osaka University Graduate School of Medi-
cine. Six samples were obtained from three patients with severe
osteoarthritis (OA) and three patients with traumatic arthritis
(TA). The HA concentrations of all samples were determined using
an ELISA kit (Seikagaku, Kogyo Co., Tokyo, Japan).
C2C12 cells were plated on 24-well plates at a density of
2  104 cells/well in 500 ll of medium. To test the effects of syno-
vial ﬂuid, 50 ll of the synovial ﬂuid from the patients and 300 ng/
ml rhBMP-2 were added to the culture medium at 24 h after plat-
ing. The controls were not treated with synovial ﬂuid. After culture
for 3 days, ALP activity was measured using the Lab Assay™ ALP
system (Wako Pure Chemicals Industries Ltd.).
2.12. Effects of HA on ALP activity in mouse calvaria cells
Mouse primary osteoblasts were isolated from the calvariae of
3-day-old C57BL/6 mice (Charles River Laboratories Japan, Inc.,
Osaka, Japan) by sequential collagenase digestion, as described
previously [20]. Cells were cultured in a-minimum essential med-
ium (Invitrogen) containing 10% FBS, 0.1 mM ascorbic acid (Sigma–
Aldrich), and 4 mM b-glycerophosphate (Sigma–Aldrich). Cellswere treated with HA at concentrations of 0, 500, and 1000 lg/
ml in the presence of 100 ng/ml rhBMP-2. After culture for 3 days,
ALP activity was measured using the Lab Assay™ ALP system
(Wako Pure Chemicals Industries Ltd.). The animal experimental
protocol was approved by the Ethics Review Committee for animal
experimentation of Osaka University School of Medicine.
2.13. Statistical analysis
All experiments were repeated at least three times. Data were
expressed as the mean ± standard deviation and analyzed by one-
way analysis of variance (ANOVA), followed by Dunnett’s test if
signiﬁcant differences were detected. Differences between groups
were considered signiﬁcant at P < 0.05.
3. Results
3.1. Expression of CD44 receptors on C2C12 and ST2 cells
Using semiquantitative RT-PCR, we clearly detected the expres-
sion of CD44 mRNA in C2C12 and ST2 cells, which corresponded to
300 base pairs (Fig. 2A). CD44 receptors were identiﬁed by immu-
nocytochemistry with green labeling, which made the cytoplasm
visible in the C2C12 (Fig. 2)B-a and ST2 (Fig. 2)B-b cells. In addition,
we used FACS to observe the temporal expression of CD44 recep-
tors on the surfaces of C2C12 and ST2 cells. The purity of the
CD44-positive cells was 80.3 ± 0.1% in C2C12 cells and
87.9 ± 0.1% in ST2 cells (Fig. 2C).
3.2. Effects of HA on osteoblastic differentiation in C2C12 and ST2 cells
based on the CD44 receptor
HA did not affect the proliferation of C2C12 (Fig. 3A) or ST2
(data not shown) cells. Fig. 3B shows that HA signiﬁcantly reduced
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trations of 50, 500, and 1000 lg/ml (14.15 ± 0.39, 95% CI 13.17–
15.12, P = 0.038, 10.80 ± 0.73, 95% CI 8.98–12.63, P = 0.0005, and
10.89 ± 0.44, 95% CI 8.98–11.19, P = 0.0004 vs control,
19.05 ± 0.61, 95% CI 17.52–20.59 respectively). Fig. 4A shows that
HA signiﬁcantly reduced ALP staining and activity in ST2 cells with
HA concentrations of 500 and 1000 lg/ml (14.04 ± 1.30, 95% CI
10.78–17.29, P = 0.0238 and 10.33 ± 0.66, 95% CI 8.67–11.99,
P = 0.0001 vs control, 16.45 ± 0.78, 95% CI 14.50–18.41 respec-
tively). Furthermore, the semiquantitative RT-PCR and real-time
PCR revealed that ALP and Runx2 mRNA expression was sup-
pressed at HA concentrations of 500 and 1000 lg/ml (Figs. 3D, F
and 4C, E). ALP staining and activity were restored by adding
CD44-blocking antibody compared to that in untreated cells
(Fig. 3C: 0 lg/ml, 16.45 ± 0.78, 95% CI 14.50–18.41; 50 lg/ml,
15.05 ± 0.51, 95% CI 13.77–16.34, P = 0.9939; 500 lg/ml,
14.04 ± 1.30, 95% CI 10.78–17.29, P = 0.6683; 1000 lg/ml,
10.33 ± 0.6683, 95% CI 8.67–11.99, P = 0.8913; Fig. 4B: 0 lg/ml,
14.39 ± 1.31, 95% CI 11.11–17.66; 50 lg/ml, 14.76 ± 1.91, 95% CI
10.00–19.52, P = 0.9714; 500 lg/ml, 14.07 ± 0.64, 95% CI 12.46–
15.67, P = 0.9810; 1000 lg/ml, 13.28 ± 1.04, 95% CI 10.68–15.88,
P = 0.6235). RT-PCR and real-time PCR showed that the CD44-
blocking antibody failed to suppress mRNA expression of any
genes, including ALP and Runx2 (Figs. 3E, G and 4D, F).Fig. 3. Effects of HA on osteoblast differentiation in C2C12 cells. (A) Effects on cell
proliferation. (B) and (C) Effects of HA on ALP staining and activity. (B) Non-treated
cells; (C) cells treated with 5 lg/ml CD44-blocking antibody. (D) and (E) Effects of
HA on osteoblast-related genes on RT-PCR. (D) Non-treated cells; (E) cells treated
with 5 lg/ml CD44-blocking antibody. (F) and (G) Effects of HA on osteoblast-
related genes on real-time PCR. (F) Non-treated cells; (G) cells treated with 5 lg/ml
CD44-blocking antibody. The asterisks indicate P < 0.05 compared with the control
without any treatment.
Fig. 3 (continued)3.3. Effect of HA on the downregulation of Smad1/5/8 phosphorylation
via CD44 receptor signaling
We investigated the molecular mechanism underlying the inhi-
bition of BMP signal transduction by HA. Smad signals were ana-
lyzed by monitoring the phosphorylation levels of a set of
receptor-activated Smads (Smad1, Smad5, and Smad8; Smad1/5/
8). The cells were treated with HA (500 lg/ml) in the presence or
absent of rhBMP-2. The phosphorylation of Smad1/5/8 by
rhBMP-2 was downregulated. When the cells were treated with
CD44-blocking antibody, the phosphorylation level of Smad1/5/8
was rescued as compared with the untreated cells (Fig. 5A, Suppl.
Fig. 1A). The protein level of total Smad1/5/8 was increased in lines
b and c because BMP accelerated the Smad pathway. In contrast,
the protein level of total Smad1/5/8 was decreased by adding
CD44-blocking antibody. Reports of a previous study indicated that
CD44 modulates Smad1 activation in the BMP signaling pathway
[7]. In our experiment, CD44-blocking antibody may have an effect
on the protein level of total Smad1/5/8 through the CD44–Smad
interaction. These results demonstrate that CD44 is involved in
the phosphorylation of Smad1/5/8 by rhBMP-2.
3.4. Activation of Rho A by HA via CD44 receptors
We measured the activity of RhoA activity by rhotekin beads in
the cells. The level of active GTP-bound RhoA increased after the
addition of 500 lg/ml HA.
Fig. 4. Effects of HA on osteoblast differentiation in ST2 cells. (A) and (B) Effects of HA on ALP staining and activity. (A) Non-treated cells; (B) cells treated with 5 lg/ml CD44-
blocking antibody. (C) and (D) Effects of HA on osteoblast-related genes on RT-PCR. (C) Non-treated cells; (D) cells treated with 5 lg/ml CD44-blocking antibody. (E) and (F)
Effects of HA on osteoblast-related genes on real-time PCR. (E) Non-treated cells; (F) cells treated with 5 lg/ml CD44-blocking antibody. The asterisks indicate differences
where P < 0.05 compared with the control without any treatment.
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antibody. The level of RhoA activity decreased as compared with
the untreated cells (Fig. 5B, Suppl. Fig. 1B).
3.5. Effects of human synovial ﬂuid on BMP-induced osteoblastic
differentiation
Fig. 6B summarizes the clinical information and HA concentra-
tions of the patients who received synovial ﬂuid. HA concentra-
tions varied between 1.7 and 2.2 mg/ml. To study the effects of
synovial ﬂuid on osteoblastic differentiation, we obtained HA con-
centrations of 50 ll from the synovial ﬂuids of patients, which cor-
responded to the signiﬁcant ranges observed in the present study.
Treatment with human synovial ﬂuid strongly suppressed ALP
activity in C2C12 cells (Fig. 6A). ALP activity was signiﬁcantly
lower than that of the control (control, 14.41 ± 0.89, 95% CI
12.19–16.63; No. 1, 4.85 ± 0.20, 95% CI 4.34–5.37, P < 0.05; No. 2,
5.61 ± 0.34, 95% CI 4.76–6.46, P < 0.05; No. 3, 6.54 ± 0.52, 95% CI
5.23–7.86, P < 0.05; No. 4, 4.92 ± 0.11, 95% CI 4.63–5.20; No. 5,
5.16 ± 0.34, 95% CI 4.31–6.01, P < 0.05; No. 6, 6.83 ± 0.35, 95% CI
5.94–7.73, P < 0.05). There was little difference in ALP activity of
the synovial ﬂuid from patients with OA (No. 1, No. 2, and No. 3)
and those with trauma (No. 4, No. 5, and No. 6).
3.6. Effects of HA on BMP-induced osteoblastic differentiation in mouse
calvaria cells
We tested mouse calvaria cells. The cells were treated with HA
at different concentrations in the presence of rhBMP-2 (100 ng/ml).HA signiﬁcantly reduced the activity of ALP at an HA concentration
of 500 and 1000 lg/ml (P = 0.0087 and P = 0.0006 vs control,
respectively; Fig. 7A). Furthermore, the activity of ALP was restored
by adding CD44-blocking antibody (10 lg/ml), as compared with
the untreated cells (P = 0.1935 and P = 0.0717 vs control, respec-
tively; Fig. 7B).
4. Discussion
In this study, we found that HA inhibited BMP-induced osteo-
blastic differentiation in C2C12 and ST2 cells. Similar effects of
HA during BMP-induced osteoblastic differentiation were observed
in mouse calvaria cells. We also investigated the signal transduc-
tion of HA inhibition during osteoblastic differentiation and
observed that CD44-blocking antibody restored the HA-mediated
downregulation of Smad1/5/8 phosphorylation and HA inhibition
during osteoblastic differentiation.
We also tested the BMP reporter assay in C2C12 cells. A lucifer-
ase reporter plasmid driven by the Id1 promoter (Id1WT4F-luc)
was provided by Dr. Katagiri (Saitama Medical School, Saitama,
Japan) [21,22]. We assayed the effect of HA addition on the activity
of a luciferase reporter with an Id1 promoter. Id1 is known to be an
early response gene to BMP-2 and to contain both a BMP-respon-
sive element (BRE) and a cAMP-response element (CRE). The eleva-
tion of luciferase activity in C2C12 cells in response to BMP-2
treatment was further downregulated by the addition of HA, indi-
cating that HA decelerates BMP signaling (Suppl. Fig. 2).
Many recent studies have focused on HA-mediated CD44 inter-
actions with downstream effectors. For example, Rho GTPase
Fig. 4 (continued)
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tumor cells [4,23,24]. Rho GTPases (RhoA, Rac1, and Cdc42) are
members of the Rho subclass of the Ras superfamily [25]. In addi-
tion, recent ﬁndings indicate that the RhoA signaling pathway has
important roles in bone remodeling. For example, in osteoblast
survival [26], the integrity of the actin cytoskeleton as well as
migration [27] and differentiation [28–30] are regulated by RhoA
signaling. We examined the effects of HA on RhoA activation in
cells. We found that HA activated RhoA, whereas a CD44-blocking
antibody inhibited this activation.
In the present study, it was unclear whether HA enhanced RhoA
activation in cells, whether RhoA activation affected BMP signal
transduction directly or whether the suppression of BMP-induced
osteoblastic differentiation was mediated via other signaling path-
ways modulated by HA. Therefore, further research is needed to
examine the molecular mechanisms, including the correlations
between HA and other receptors.
We also found that human synovial ﬂuid negatively regulated
BMP-induced osteoblastic differentiation in vitro. We analyzed
the molecular size of synovial ﬂuid HA, which was approximately
50–2000kDa (data not shown). The synovial ﬂuid of our samplescontained various sizes of HA compared to Artz (900–1200kDa).
In this study, we detected no differences in ALP activity in the
synovial ﬂuid samples, although the size or viscosity of the compo-
nents could have affected the biological activity of HA. In human
synovial ﬂuid, many other components may have relevant biolog-
ical activities in human synovial ﬂuid [31]. In our future study,
other components in addition to HA should be examined.
Clinically, intra-articular HA injection is one of the treatment of
osteoarthritis (OA) [32]. HA contributes to the lubrication, shock
absorption, hydration, and nutrition of the joint tissue, as well as
to articular cartilage formation and repair [33]. OA is a chronic
degenerative joint disorder, which is characterized by articular car-
tilage destruction and bone formation such as osteophyte forma-
tion and subchondral bone screlosis [34,35]. Since it has been
reported that HA concentration of the joint is reduced in OA
patients [36], HA may have therapeutic signiﬁcance in OA patient
by inhibiting bone formation.
In conclusion, HA negatively regulates BMP-induced osteoblas-
tic differentiation via the CD44 receptor, suggesting that HA may
have a signiﬁcant role in bone metabolism in the progression of
OA.
Fig. 5. Effects of HA via CD44 on Smad1/5/8 phosphorylation and the activation of
RhoA in C2C12 cells. (A) Effects of HA via CD44 on Smad1/5/8 phosphorylation. (a, b,
c: non-treated cells; d, e: cells treated with 5 lg/ml CD44-blocking antibody). (B)
Activation of RhoA by HA via CD44. (a, b, d: non-treated cells; c; cells treated with
5 lg/ml CD44-blocking antibody; e: cells treated with control IgG). Each experi-
ment was performed a minimum of three times.
Fig. 6. (A) Effects of human synovial ﬂuids on ALP activity in C2C12 cells, where the
ALP activity is shown (control: cells not treated with synovial ﬂuids; 1–6: cells
treated with No. 1–No. 6 each synovial ﬂuid). The asterisks indicate P < 0.05
compared with the control without any treatment. (B) Proﬁles of clinical synovial
ﬂuid samples (No. 1, No. 2, No. 3: osteoarthritis; No. 4, No. 5, No. 6: traumatic
arthritis). The HA concentrations of all samples were measured in duplicates.
Fig. 7. Effects of hyaluronan (HA) on the alkaline phosphatase (ALP) activity levels
in mouse calvaria cells. (A) Non-treated cells; (B) cells treated with 10 lg/ml CD44-
blocking antibody. The data are the means ± S.D. based on three independent
experiments performed using independent samples (n = 3). The asterisks indicate
P < 0.05 compared with the control without any treatment.
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